Drugs by condition
Drugs approved for myasthenia gravis
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
13
Still marketed, NDA or BLA
Drug classes
5
Novel drugs
8
New molecular entities and new biologics
In development
15
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for myasthenia gravis.
- Imaavy (Nipocalimab-Aahu) · Janssen Biotech NovelPriority reviewOrphanApr 29, 2025
- Epysqli (Eculizumab-Aagh) · Samsung Bioepis CO LTD Jul 19, 2024
- Bkemv (Eculizumab-Aeeb) · Amgen INC May 28, 2024
- Rystiggo (Rozanolixizumab-Noli) · Ucb INC NovelPriority reviewOrphanJun 26, 2023
- Vyvgart Hytrulo (Efgartigimod Alfa and Hyaluronidase-Qvfc) · Argenx Bv Priority reviewOrphanJun 20, 2023
All approved drugs for myasthenia gravis, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 10 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Complement Inhibitor (4)
Neonatal Fc Receptor Blocker (2)
CD19-directed Cytolytic Antibody (1)
- Uplizna Inebilizumab-Cdon · Viela Bio · 2020
Endoglycosidase (1)
- Vyvgart Hytrulo Efgartigimod Alfa and Hyaluronidase-Qvfc · Argenx Bv · 2023
Class not listed in FDA's data (5)
- Imaavy Nipocalimab-Aahu · Janssen Biotech · 2025
- Protopam Chloride Pralidoxime Chloride · Baxter Hlthcare Corp · 1964
- Mestinon Pyridostigmine Bromide · Bausch · 1955
- Mestinon Pyridostigmine Bromide · Bausch · 1965
- Mestinon Pyridostigmine Bromide · Bausch · 1959
Drugs in development for myasthenia gravis
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- EmpasiprubartARGX-117Phase 39 trials
argenx · Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
- FelzartamabPhase 38 trials
Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- CemdisiranALN-CC5Phase 35 trials
Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)
- ClaseprubartDNTH103Phase 34 trials
Dianthus Therapeutics · Myasthenia Gravis, Generalized, Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- B007Phase 33 trials
Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis
- KYV-101Phase 32 trials
Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- SHR-2173Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy
- Descartes-08Phase 24 trials
Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
- NMD670Phase 23 trials
NMD Pharma A/S · Myasthenia Gravis, Myasthenia Gravis, MuSK, Charcot-Marie-Tooth Disease
- AritinerceptPhase 21 trial
Aurinia Pharmaceuticals Inc. · Myasthenia Gravis, Generalized
- CNP-106Phase 21 trial
COUR Pharmaceutical Development Company, Inc. · Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis
More on myasthenia gravis: recruiting trials · published research
Related in neurology: Alzheimer's disease · Parkinson's disease · Multiple sclerosis · Epilepsy and seizures · Migraine · ALS (amyotrophic lateral sclerosis) · Spinal muscular atrophy · Duchenne muscular dystrophy · Huntington's disease chorea · Tardive dyskinesia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.